

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (previously presented) A vaccine composition comprising at least one group A Streptococcal antigen and a proteosome adjuvant.
2. (previously presented) A vaccine composition according to claim 1 wherein the antigen comprises an *S. pyogenes* M protein peptide.
3. (previously presented) A vaccine composition according to claim 1 wherein the antigen comprises a fragment of the M protein from the C-terminal region of between 6 and 25 amino acids in length.
4. (currently amended) A vaccine composition according to claim 1 wherein the antigen has the sequence ASREAKKQVEQKALE (SEQ ID NO:1).
5. (previously presented) A vaccine composition according to claim 2 wherein the antigen is flanked by amino acid sequences to maintain helical folding of the antigen.
6. (currently amended) A vaccine composition according to claim 5 wherein the peptideantigen has the sequence KQAEDKVKASREAKKQVEKALEQLEDKVK(SEQ ID NO:2).
7. (previously presented) A vaccine composition according to claim 1 wherein the antigen is selected from an MtsA peptide or a protein H peptide.

8. (previously presented) A vaccine composition according to claim 1 wherein the antigenic peptide further comprises a C- or N-terminal hydrophobic moiety for insertion of the antigenic peptide into proteosome adjuvant vesicles.
9. (previously presented) A vaccine composition according to claim 1 for parenteral or oral administration.
10. (previously presented) A vaccine composition according to claim 9 for intranasal administration.
11. (previously presented) A vaccine composition according to claim 1 for use in the treatment or prophylaxis of a group A Streptococcal infection in an individual.
12. (previously presented) A vaccine composition according to claim 11 wherein the composition is administered intranasally to the individual.
13. (previously presented) A vaccine composition according to claim 11 wherein administration of the composition to the individual induces a mucosal immune response.
14. (previously presented) A vaccine composition according to claim 11, wherein administration of the vaccine composition induces a serum immune response.
15. (previously presented) A vaccine composition according to claim 11 wherein the vaccine composition is administered intranasally to the individual and treatment or prophylaxis of group A Streptococcal infection is produced via reduction or prevention of bacterial colonisation of the throat.
16. (previously presented) A method of treatment or prophylaxis of group A Streptococcal

infection in an individual comprising administering a vaccine composition according to claim 1 to the individual.

17. (previously presented) A method according to claim 16 wherein said vaccine composition is administered intranasally to said individual.

18. (previously presented) A method according to claim 17 wherein the treatment or prophylaxis group A Streptococcal infection is produced via prevention or reduction of bacterial colonisation of the throat.